Table 3.

Bevacizumab Treatment Response

	N (%)
Patients Remaining on Therapy	8 (11)
Patients Only Receiving a Single Dose	7 (10)
Patients Treated for > 12 Months	9 (13)
Reason For Discontinuation of Therapy
PD	56 (89)
Toxicity	4 (6)
Bleeding	1
Deep Venous Thrombosis	1
Failure to Thrive	1
Myocardial Infarction	1
Unrelated	2
Unknown	1
Best Radiographic Response to Therapy
PR	2
SD	28
PD	31
Deaths	47
PFS events	52
	Median in Months
Time on Treatment	2.8 (Range 0.5 – 38.7)
Progression Free Survival	1.9 (95% CI 1.7 – 4.1)
Overall Survival	11.5 (95% CI 6.4 – 17.4)